Here's Why Assembly Biosciences Stock Soared Today
Shares of Assembly Biosciences (NASDAQ: ASMB) gained over 41% today after the company announced an update on its hepatitis B virus (HBV) programs.
The first update, from a phase 2a study evaluating the lead drug candidate ABI-H0731, suggests that the pipeline asset is effective in reducing DNA and RNA signatures of the virus. The second update, from a phase 1b study of a next-generation drug candidate named ABI-H2158, suggests that the asset can reduce the activity of the virus after just 14 days.
As of 3:53 p.m. EDT, the stock had settled to a 38.2% gain.
Source Fool.com
